This is a working overview of modified GRF(1-29), written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-08 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
Oscar Tiegs returned to his area of doctoral studies for what was to be his last research, an exhaustive study of the flight muscles of insects and other arthropod muscles published in 1955. This analysis of the comparative myology and evolution of wide range of insect's flight muscles showed how such muscles evolved structurally at a histological level. He showed that the histogenesis of muscle in orthoptera (butterflies, moths, etc.) and simpler insects by the repeated division of rudimentary muscle fibres, but in higher orders of insect, free individual myoblasts applicate to young muscle fibres laying down a new fibril, contributing sarcoplasm and nuclei. In 1956 Oscar Tiegs was awarded the Clarke Medal by the Royal Society of New South Wales, although the Australian Academy of Science has him listed, incorrectly, as receiving this award in 1928.
President Jimmy Carter, which ensured that control over the Panama Canal would pass to Panama in 1999. These treaties, as well as a new labor code that included maternity leave, collective bargaining rights, and bonus pay, made Torrijos popular in Panama despite the absence of democratic elections. Torrijos's relationship with Noriega was symbiotic; Torrijos provided the political acumen, while Noriega enforced his unpopular decisions with force, when necessary. Noriega would provide intelligence and carry out covert operations that were critical to Torrijos successfully negotiating the release of the Panama Canal from the U.S. Upon seizing power in 1968, Torrijos's government had passed legislation favorable to foreign corporations, including banks in the U.S. The following years saw a large expansion in international business activity and the influx of foreign capital, thereby giving participating corporations a stake in the continued existence of the military government. The government used its access to foreign capital to borrow extensively, fueling a rapid expansion of the state bureaucracy that contributed to the military regime's stability. Panama's borrowing peaked in 1978 when the Panama Canal treaty was being negotiated, a time at which the Carter government was particularly supportive of the Torrijos regime. The Carter administration's interest in signing a new treaty led it to largely overlook the increasing militarization of the Panamanian government, and its involvement in drug-trafficking.
== Description == Sophora flavescens can grow to a height of 2 m (6.6 ft). Its stem is marked with stripes and covered in soft hairs when young. The leaves are usually 20–25 cm (8–10 in) long, with lanceolate stipules and 13–25 elliptic, ovate, or lanceolate leaflets. The plant produces terminal racemes measuring 15–25 cm (6–10 in), with numerous flowers spaced widely apart. The flowers have slender pedicels and linear bracts with white, pale yellow, purple-red, or red spoon-shaped petals. It blooms from June to August and fruits from July to October.
Sources: en.wikipedia.org
=== Lactic acidosis === A randomized controlled trial in children with congenital lactic acidosis found that while DCA was well tolerated, it was ineffective in improving clinical outcomes. A separate trial of DCA in children with MELAS (a syndrome of inadequate mitochondrial function, leading to lactic acidosis) was halted early, as all 15 of the children receiving DCA experienced significant nerve toxicity without any evidence of benefit from the medication. A randomized controlled trial of DCA in adults with lactic acidosis found that while DCA lowered blood lactate levels, it had no clinical benefit and did not improve hemodynamics or survival. Thus, while early case reports and pre-clinical data suggested that DCA might be effective for lactic acidosis, subsequent controlled trials have found no clinical benefit of DCA in this setting. In addition, clinical trial subjects were incapable of continuing on DCA as a study medication owing to progressive toxicities.
Lysergic acid methylpropylamide (LAMPA, LAMP, or LMP), also known as LMP-55 or as N-methyl-N-propyllysergamide (MPLA), is a structural analogue of lysergic acid diethylamide (LSD) that has been studied as a potential treatment for alcoholism. In animal studies, LAMPA was found to be nearly equipotent to ECPLA and MIPLA for inducing a head-twitch response. LAMPA appears to be significantly less potent than LSD in humans, producing little to no noticeable effects at doses of 100 μg. It shows reduced-efficacy partial agonism of the serotonin 5-HT2A receptor relative to LSD, which may be responsible for its equivocal hallucinogenic effects. LAMPA is not an explicitly controlled substance in the United States, but may be considered implicitly controlled as it is an isomer of LSD. The drug is not a controlled substance in Canada as of 2025.
== Description == It is an annual plant that grows 1 to 3 metres (3 to 10 feet) high and is sticky haired on all parts. The stems are thick and not very branched. The leaves can be over 50 centimetres (1 ft 8 in) long with the blades ovate to elliptical, or obovate, pointed towards the front and, at the base, run down the stem or are sessile, encompassing the stem. The scented inflorescences are multi-branched panicles. The flower stalks are 5 to 15 millimetres (3⁄16 to 9⁄16 in) long. The calyx is 12 to 18 millimetres (1⁄2 to 11⁄16 in) and is covered with uneven 4 to 8 mm (3⁄16 to 5⁄16 in) narrow pointed calyx lobes shorter than the calyx tube. The crown is plate-shaped, the coronet is white, pink or red, the corolla tube greenish-cream, pink or red. The corolla tube has a total length of 3.5 to 4.5 cm (1+3⁄8 to 1+3⁄4 in) and is 3 to 5 mm (1⁄8 to 3⁄16 in) wide in the lower part and widens to 7 to 12 mm (1⁄4 to 1⁄2 in) in the upper part. The coronet is lobed or pentagonal. The stamens are designed unevenly and start below the center of the corolla tube. The anthers of the four longer stamens are close to the opening of the corolla tube or are slightly above it. The fifth stamen is significantly shorter than both longer pairs. The stamens have a length of 2.5 to 3.5 cm (1 to 1+3⁄8 in), significantly longer than the anthers, and are hairy at the base. The fruit is a 1.5 to 2 cm (9⁄16 to 13⁄16 in) long capsule that is narrowly elliptical-to-egg-shaped. It can stand out over the calyx or be enclosed by it.
Dry ice is the solid form of carbon dioxide. It is commonly used for temporary refrigeration as CO2 does not have a liquid state at normal atmospheric pressure and sublimes directly from the solid state to the gas state. It is used primarily as a cooling agent, but is also used in fog machines at theatres for dramatic effects. Its advantages include lower temperature than that of water ice and not leaving any residue (other than incidental frost from moisture in the atmosphere). It is useful for preserving frozen foods (such as ice cream) where mechanical cooling is unavailable. Dry ice sublimes at 194.7 K (−78.5 °C; −109.2 °F) at Earth atmospheric pressure. This extreme cold makes the solid dangerous to handle without protection from frostbite injury. While carbon dioxide is not toxic at normal atmospheric concentrations, dry ice can create dangerous CO₂ levels in poorly ventilated spaces. The outgassing from it can cause hypercapnia (abnormally elevated carbon dioxide levels in the blood) due to a buildup in confined locations.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.